Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 189
interventional 145
Observational 39
Registry 5

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 70
Device 26
Biological 15
Other 5
Procedure 5
Drug|placebo 4
Drug|Other 3
Behavioral 2
Biological|Other 2
Dietary Supplement|placebo 2
Genetic 2
Behavioral|Other 1
Biological|Combination Product 1
Combination Product 1
Device|Drug 1
Device|Procedure 1
Diagnostic Test|Drug|Other 1
Dietary Supplement|Drug 1
Dietary Supplement|Other 1
Drug|Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 75
NA 10
France 7
United States|Canada 5
Israel 3
Italy 3
Turkey 3
United States|United Kingdom 3
Australia 2
Brazil 2
China 2
Germany 2
Hong Kong 2
Spain 2
United Kingdom 2
United States|Canada|Germany|Netherlands|United Kingdom 2
Austria 1
Austria|France|Germany 1
Austria|France|Germany|Spain|United Kingdom 1
Belgium|Italy 1
Canada|Ireland 1
Denmark|Germany|Norway 1
Germany|Hungary|United Kingdom 1
India 1
Indonesia 1
Jordan 1
Korea, Republic of 1
Lebanon 1
Mexico 1
Poland 1
Sweden 1
Thailand 1
United States|Belgium|Canada|France 1
United States|France|Germany|Portugal 1
United States|France|United Kingdom 1
United States|United Arab Emirates 1

Sites per Study

Site_count Study_Count
1 78
2 14
3 5
4 3
5 6
6 7
7 4
8 3
9 6
11 2
12 2
13 3
14 1
17 2
18 1
19 2
20 2
22 1
23 1
25 1
36 1

Phase

Phase Study_Count
N/A 60
Phase 2 23
Phase 1 22
Phase 1/Phase 2 19
Phase 3 12
Phase 2/Phase 3 4
Phase 4 4
Early Phase 1 1

Number of Arms

Number_of_Arms Count_of_Studies
1 38
2 31
3 13
4 2
5 2
6 1
7 1
9 1
12 1
NA 55

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 50 2.0000 5.0 7.00000 10.0000 63.00 32.00 1.00
1st Qu. 50 18.7500 10.0 15.75000 48.0000 63.75 90.75 30.25
Median 50 46.5000 22.0 20.50000 78.0000 82.00 207.00 76.00
Mean 50 133.0192 22.6 24.22222 139.7619 109.00 171.00 113.25
3rd Qu. 50 101.2500 30.0 29.50000 167.0000 127.25 238.50 159.00
Max. 50 1200.0000 53.0 50.00000 850.0000 209.00 279.00 300.00

Trial Group Type

group_type Group_Count
Experimental 123
NA 55
Active Comparator 35
Placebo Comparator 12
Sham Comparator 9
Other 7
No Intervention 5

Intervention Model

intervention_model Study_Count
Single Group Assignment 46
NA 41
Parallel Assignment 40
Sequential Assignment 11
Crossover Assignment 4
Factorial Assignment 3

Primary Purpose

primary_purpose Study_Count
Treatment 123
Other 10
Basic Science 2
Device Feasibility 2
Diagnostic 2
Prevention 2
NA 2
Health Services Research 1
Screening 1

Observational Studies

Studies by Country

Country Study_Count
United States 21
United Kingdom 3
France 2
Israel 2
Japan 2
Germany 1
NA 1
Russian Federation 1
Taiwan 1
United States|Belgium|Brazil|Canada|France|Germany|Israel|Netherlands|Poland|United Kingdom 1
United States|Canada|Denmark|Germany|Netherlands|Switzerland|United Kingdom 1
United States|Canada|France|Germany|Netherlands|United Kingdom 1
United States|Canada|Israel|Singapore|United Kingdom 1
United States|China|India|Pakistan 1

Sites per Study

Site_count Study_Count
1 23
2 4
3 1
4 1
5 1
6 1
9 1
16 2
17 1
19 1
25 1
26 1
52 1

Enrollment Metrics

Measure Observational
Min 1.0000
1st Qu 46.2500
Median 82.5000
Mean 662.3158
3rd Qu 236.7500
Max 6618.0000

Observation Model

observational_model Study_Count
Cohort 15
NA 8
Case-Control 6
Case-Only 3
Case Control 2
Case-Crossover 1
Defined Population, Natural History 1
Ecologic or Community 1
Family-Based 1
Other 1

Time Perspective

time_perspective Study_Count
Prospective 23
NA 7
Retrospective 5
Cross-Sectional 3
Other 1

Registries

Studies by Country

Country Study_Count
France 1
Mexico 1
Russian Federation 1
United States 1
United States|Australia 1

Sites per Study

Site_count Study_Count
1 2
2 1
3 1
6 1

Enrollment Metrics

Measure Registries
Min 28.0
1st Qu 1000.0
Median 17000.0
Mean 11605.6
3rd Qu 20000.0
Max 20000.0

Registry Model

observational_model Study_Count
Cohort 2
Case-Only 1
Family-Based 1
Other 1

Time Perspective

time_perspective Study_Count
Prospective 5

Follow-up

target_duration Study_Count
100 Years 1
20 Years 1
3 Years 1
5 Years 1
8 Months 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03381235 Exercise and RP (AVAMC and Emory) https://ClinicalTrials.gov/show/NCT03381235 Completed Emory University 2018-11-28
NCT03374657 A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT03374657 Recruiting Novartis 2026-07-28
NCT03368027 Effectiveness of a Cognitive-behavioral Program of Coping With Psychological Stress in People With Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT03368027 Completed Universidad de Granada 2018-12-03
NCT03328130 Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene https://ClinicalTrials.gov/show/NCT03328130 Recruiting Horama S.A. 2022-09-30
NCT03316560 Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations https://ClinicalTrials.gov/show/NCT03316560 Recruiting Applied Genetic Technologies Corp 2023-03-31
NCT03252847 Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) Retinitis Pigmentosa GTPase Regulator (RPGR) https://ClinicalTrials.gov/show/NCT03252847 Active, not recruiting MeiraGTx UK II Ltd 2020-11-30
NCT03248388 Argus II/ORCAM Device Study https://ClinicalTrials.gov/show/NCT03248388 Recruiting Mayo Clinic 2021-12-31
NCT03116113 A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT03116113 Recruiting NightstaRx Ltd, a Biogen Company 2021-03-31
NCT03078309 The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients https://ClinicalTrials.gov/show/NCT03078309 Recruiting Hadassah Medical Organization 2020-08-31
NCT03073733 Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT03073733 Active, not recruiting jCyte, Inc 2020-09-30
NCT03063021 The FIGHT-RP1 Study https://ClinicalTrials.gov/show/NCT03063021 Completed Johns Hopkins University 2019-02-11
NCT03057496 Collision Warning Device for Blind and Visually Impaired https://ClinicalTrials.gov/show/NCT03057496 Completed Massachusetts Eye and Ear Infirmary 2019-11-08
NCT02909985 Visual Activity Evoked by Infrared in Humans After Dark Adaptation https://ClinicalTrials.gov/show/NCT02909985 Completed University of New Mexico 2016-08-31
NCT02837640 Studying a Potential Protective Effect of L-Dopa on Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT02837640 Recruiting Beirut Eye Specialist Hospital 2017-06-30
NCT02720640 Safety and Efficacy of the Alpha AMS Subretinal Implant https://ClinicalTrials.gov/show/NCT02720640 Completed University of Oxford 2017-10-31
NCT02709876 Autologous Bone Marrow-Derived CD34+, CD133+, and CD271+ Stem Cell Transplantation for Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT02709876 Active, not recruiting Stem Cells Arabia 2020-09-30
NCT02670980 Compensation for Blindness With the Intelligent Retinal Implant System (IRIS V2) in Patients With Retinal Dystrophy https://ClinicalTrials.gov/show/NCT02670980 Completed Pixium Vision SA 2019-05-31
NCT02614651 AUgmented REality for the Visually Impaired - Part 1 https://ClinicalTrials.gov/show/NCT02614651 Completed Centre Hospitalier Universitaire de Nīmes 2017-04-20
NCT02609165 Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema https://ClinicalTrials.gov/show/NCT02609165 Completed Ospedale San Raffaele 2017-02-28
NCT03011541 Stem Cell Ophthalmology Treatment Study II https://ClinicalTrials.gov/show/NCT03011541 Recruiting MD Stem Cells 2022-01-31
NCT03406416 Study of a Suprachoroidal Retinal Prosthesis https://ClinicalTrials.gov/show/NCT03406416 Active, not recruiting Mobius Medical Pty Ltd. 2020-12-31
NCT03845218 Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures https://ClinicalTrials.gov/show/NCT03845218 Recruiting National Institutes of Health Clinical Center (CC) 2021-03-30
NCT02556736 RST-001 Phase I/II Trial for Advanced Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT02556736 Active, not recruiting Allergan 2020-12-03
NCT02464436 Safety and Tolerability of hRPC in Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT02464436 Recruiting ReNeuron Limited 2020-01-31
NCT02320812 Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT02320812 Completed jCyte, Inc 2017-07-19
NCT02280135 Clinical Trial of Intravitreal Injection of Autologous Bone Marrow Stem Cells in Patients With Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT02280135 Completed Red de Terapia Celular 2017-03-31
NCT02244996 Cone Rescue in Retinitis Pigmentosa by the Treatment of Lycium Barbarum https://ClinicalTrials.gov/show/NCT02244996 Completed The Hong Kong Polytechnic University 2016-04-30
NCT02140164 Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT02140164 Completed National Institutes of Health Clinical Center (CC) 2015-11-30
NCT02110225 A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP) https://ClinicalTrials.gov/show/NCT02110225 Completed Dompé Farmaceutici S.p.A 2015-11-30
NCT02086890 Electro-acupuncture and Transcorneal Electrical Stimulation (TES) for Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT02086890 Active, not recruiting Nova Southeastern University 2020-06-30
NCT03326336 Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT03326336 Recruiting GenSight Biologics 2021-12-31
NCT01866397 Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration https://ClinicalTrials.gov/show/NCT01866397 Completed Medical University of Vienna 2002-03-31
NCT01864486 Restoring Vision With the Intelligent Retinal Implant System (IRIS V1)in Patients With Retinal Dystrophy https://ClinicalTrials.gov/show/NCT01864486 Completed Pixium Vision SA 2017-10-13
NCT01847365 TES for the Treatment of RP https://ClinicalTrials.gov/show/NCT01847365 Completed University of Oxford 2015-02-28
NCT01837901 Transcorneal Electrostimulation for Therapy of Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT01837901 Completed Okuvision GmbH 2013-08-31
NCT01835002 Transcorneal Electrical Stimulation - Multicenter Safety Study https://ClinicalTrials.gov/show/NCT01835002 Completed Okuvision GmbH 2014-07-31
NCT01736059 Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy https://ClinicalTrials.gov/show/NCT01736059 Enrolling by invitation University of California, Davis 2022-01-31
NCT01604356 Acupuncture for the Treatment of Vision Loss Due to Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT01604356 Completed Johns Hopkins University 2013-12-31
NCT01603576 Pilot Study of a Suprachoroidal Retinal Prosthesis https://ClinicalTrials.gov/show/NCT01603576 Completed Center for Eye Research Australia 2014-08-31
NCT03963154 Interventional Study of Implantation of hESC-derived RPE in Patients With RP Due to Monogenic Mutation https://ClinicalTrials.gov/show/NCT03963154 Recruiting Centre d’Etude des Cellules Souches 2021-12-15
NCT01560715 Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT01560715 Completed University of Sao Paulo 2013-01-31
NCT01543906 Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65) https://ClinicalTrials.gov/show/NCT01543906 Completed QLT Inc. 2014-07-31
NCT01531348 Feasibility and Safety of Human Bone Marrow-derived Mesenchymal Stem Cells by Intravitreal Injection in Patients With Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT01531348 Enrolling by invitation Mahidol University 2020-12-31
NCT01530659 Retinal Imaging of Subjects Implanted With Ciliary Neurotrophic Factor (CNTF)-Releasing Encapsulated Cell Implant for Early-stage Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT01530659 Active, not recruiting Neurotech Pharmaceuticals 2019-08-31
NCT01521793 Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01) https://ClinicalTrials.gov/show/NCT01521793 Completed QLT Inc. 2014-05-31
NCT01497379 Safety & Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients https://ClinicalTrials.gov/show/NCT01497379 Completed Retina Implant AG 2014-01-31
NCT01399515 Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT01399515 Completed Seoul National University Hospital 2013-08-31
NCT02617966 Rod and Cone Mediated Function in Retinal Disease https://ClinicalTrials.gov/show/NCT02617966 Recruiting National Institutes of Health Clinical Center (CC) 2024-12-30
NCT04356716 Sildenafil for Treatment of Choroidal Ischemia https://ClinicalTrials.gov/show/NCT04356716 Recruiting Columbia University 2021-04-30
NCT04319809 Object Finder for a Retinal Prosthesis https://ClinicalTrials.gov/show/NCT04319809 Active, not recruiting Minnesota HealthSolutions 2021-04-30
NCT04315025 Safety Issues of Peribulbar Injection of UC-MSC in Patients With Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT04315025 Completed PT. Prodia Stem Cell Indonesia 2019-06-20
NCT04295304 NR600 System Retinal Prosthesis for Patients With Retinal Degenerative Diseases https://ClinicalTrials.gov/show/NCT04295304 Recruiting Nano Retina 2021-12-30
NCT04285398 Prospective Natural History Study of Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT04285398 Recruiting SparingVision 2021-06-01
NCT04284293 CNS10-NPC for the Treatment of RP https://ClinicalTrials.gov/show/NCT04284293 Recruiting Cedars-Sinai Medical Center 2022-04-30
NCT04278131 BS01 in Patients With Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT04278131 Recruiting Bionic Sight LLC 2022-06-30
NCT04252534 Management of Retinitis Pigmentosa Via Electromagnetic Stimulation and Platelet Rich Plasma https://ClinicalTrials.gov/show/NCT04252534 Completed Ankara Universitesi Teknokent 2019-12-30
NCT04238858 Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT04238858 Completed Ankara Universitesi Teknokent 2017-02-28
NCT04234438 Management of Cystoid Macular Edema Secondary to Retinitis Pigmentosa Via Subliminal Micropulse Yellow Laser https://ClinicalTrials.gov/show/NCT04234438 Completed Ankara Universitesi Teknokent 2019-10-30
NCT04224207 Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton’s Jelly Derived Mesenchymal Stem Cells https://ClinicalTrials.gov/show/NCT04224207 Completed Ankara Universitesi Teknokent 2019-10-30
NCT04141891 Advancing Understanding of Transportation Options https://ClinicalTrials.gov/show/NCT04141891 Recruiting University of Colorado, Denver 2023-08-01
NCT04129021 Multimodal Ophthalmic Imaging https://ClinicalTrials.gov/show/NCT04129021 Recruiting Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts 2023-06-30
NCT04123626 A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene https://ClinicalTrials.gov/show/NCT04123626 Recruiting ProQR Therapeutics 2021-10-07
NCT04120883 Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO) https://ClinicalTrials.gov/show/NCT04120883 Recruiting University of Michigan 2022-10-31
NCT04068207 Minocycline Treatment in Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT04068207 Recruiting Sun Yat-sen University 2021-12-01
NCT04008771 Intravitreal Injection of SeeQ CdSe 655 Alt Nanoparticles for Patients With Degenerative Retinal Diseases https://ClinicalTrials.gov/show/NCT04008771 Completed 2C Tech Corp 2014-12-19
NCT03999021 FIGHT-RP 1 Extension Study https://ClinicalTrials.gov/show/NCT03999021 Active, not recruiting Johns Hopkins University 2021-06-30
NCT03780257 Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene https://ClinicalTrials.gov/show/NCT03780257 Recruiting ProQR Therapeutics 2021-12-31
NCT03772938 Stem Cells Therapy in Degenerative Diseases of the Retina https://ClinicalTrials.gov/show/NCT03772938 Enrolling by invitation Pomeranian Medical University Szczecin 2020-02-28
NCT03635645 Experimental and Clinical Studies of Retinal Stimulation https://ClinicalTrials.gov/show/NCT03635645 Recruiting University of Michigan 2020-10-31
NCT03444961 CAREN Argus Rehab (CARE) Study https://ClinicalTrials.gov/show/NCT03444961 Completed The Cleveland Clinic 2018-06-20
NCT01256697 The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions im Patients With Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT01256697 Completed Sheba Medical Center 2009-04-30
NCT01235624 Autosomal Dominant Retinitis Pigmentosa: Prevalence of Known Genes Identification of New Loci / Genes https://ClinicalTrials.gov/show/NCT01235624 Completed University Hospital, Montpellier 2013-04-30
NCT01233609 Trial of Oral Valproic Acid for Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT01233609 Completed Foundation Fighting Blindness 2015-12-31
NCT01068561 Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT01068561 Completed University of Sao Paulo 2010-01-31
NCT01024803 Safety and Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients https://ClinicalTrials.gov/show/NCT01024803 Completed Retina Implant AG 2017-04-30
NCT01014052 Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations https://ClinicalTrials.gov/show/NCT01014052 Completed QLT Inc. 2012-08-31
NCT03944239 Safety and Efficacy of Subretinal Transplantation of Clinical Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT03944239 Recruiting Chinese Academy of Sciences 2021-10-31
NCT04448860 Validation of Standardized Test Protocols to Assess the Impact of Visual Pathologies in Daily Life Activities https://ClinicalTrials.gov/show/NCT04448860 Recruiting Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts 2023-10-04
NCT00804102 Transcorneal Electrical Stimulation Therapy for Retinal Disease https://ClinicalTrials.gov/show/NCT00804102 Completed Okuvision GmbH 2011-04-30
NCT01680510 The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil https://ClinicalTrials.gov/show/NCT01680510 Recruiting Sheba Medical Center 2020-12-31
NCT00717080 The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction https://ClinicalTrials.gov/show/NCT00717080 Completed Aurolab 2010-05-31
NCT00661479 An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT00661479 Completed Allergan 2009-12-31
NCT00515814 Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors https://ClinicalTrials.gov/show/NCT00515814 Completed Retina Implant AG 2009-12-31
NCT00461435 Slowing the Degenerative Process, Long Lasting Effect of Hyperbaric Oxygen Therapy in Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT00461435 Completed Azienda Policlinico Umberto I NA
NCT00447993 A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT00447993 Completed Neurotech Pharmaceuticals 2009-10-31
NCT00447980 A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT00447980 Completed Neurotech Pharmaceuticals 2010-07-31
NCT00346333 Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A https://ClinicalTrials.gov/show/NCT00346333 Completed National Eye Institute (NEI) 2008-12-31
NCT00345917 Safety Study in Retinal Transplantation for Retinitis Pigmentosa. https://ClinicalTrials.gov/show/NCT00345917 Completed Radtke, Norman D., M.D. 2012-03-31
NCT00279500 Feasibility Study of a Chronic Retinal Stimulator in Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT00279500 Completed Second Sight Medical Products 2014-12-31
NCT00100230 DHA and X-Linked Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT00100230 Completed Retina Foundation of the Southwest 2012-05-31
NCT00000970 A Study of Foscarnet Plus Ganciclovir in the Treatment of Cytomegalovirus of the Eye in Patients With AIDS Who Have Already Been Treated With Ganciclovir https://ClinicalTrials.gov/show/NCT00000970 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00029289 Effects of Lutein in Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT00029289 Completed National Center for Complementary and Integrative Health (NCCIH) NA
NCT00002437 The Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS https://ClinicalTrials.gov/show/NCT00002437 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002432 A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS https://ClinicalTrials.gov/show/NCT00002432 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002377 A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes https://ClinicalTrials.gov/show/NCT00002377 Completed Hoffmann-La Roche 2002-12-31
NCT00002356 The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes https://ClinicalTrials.gov/show/NCT00002356 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002355 A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes https://ClinicalTrials.gov/show/NCT00002355 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002321 A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis https://ClinicalTrials.gov/show/NCT00002321 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002299 The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS https://ClinicalTrials.gov/show/NCT00002299 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002257 A Randomized Controlled Study of the Efficacy and Safety of Maintenance Treatment With Oral Ganciclovir for Newly Diagnosed Cytomegalovirus Retinitis in People With AIDS https://ClinicalTrials.gov/show/NCT00002257 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002247 A Randomized Study Comparing the Safety and Efficacy of Two Regimens of Oral Ganciclovir to Intravenous Ganciclovir Maintenance Therapy for Cytomegalovirus Retinitis in People With AIDS Who Have Received Prior Ganciclovir Therapy https://ClinicalTrials.gov/show/NCT00002247 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002222 A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS https://ClinicalTrials.gov/show/NCT00002222 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002187 A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis https://ClinicalTrials.gov/show/NCT00002187 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002169 A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis https://ClinicalTrials.gov/show/NCT00002169 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002156 A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR ) https://ClinicalTrials.gov/show/NCT00002156 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002142 An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS https://ClinicalTrials.gov/show/NCT00002142 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002135 An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access https://ClinicalTrials.gov/show/NCT00002135 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002134 A Randomized, Controlled Study of the Safety and Preventive Efficacy of Oral Ganciclovir When Used in Conjunction With An Intravitreal Ganciclovir Implant in the Treatment of Cytomegalovirus Retinitis https://ClinicalTrials.gov/show/NCT00002134 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002125 A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium) https://ClinicalTrials.gov/show/NCT00002125 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002070 Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis https://ClinicalTrials.gov/show/NCT00002070 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002039 An Open Study of Foscarnet Treatment First Episode CMV-Retinitis in AIDS Patients https://ClinicalTrials.gov/show/NCT00002039 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002034 A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDS https://ClinicalTrials.gov/show/NCT00002034 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002025 Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient https://ClinicalTrials.gov/show/NCT00002025 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002016 A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis https://ClinicalTrials.gov/show/NCT00002016 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002015 An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children https://ClinicalTrials.gov/show/NCT00002015 Completed NIH AIDS Clinical Trials Information Service NA
NCT00001999 A Pilot Study to Obtain Preliminary Information Regarding the Efficacy and Safety of the Combination of Immune Globulin and Ganciclovir as Compared to Ganciclovir Alone in the Treatment of Sight-Threatening CMV Retinitis in Patients With AIDS https://ClinicalTrials.gov/show/NCT00001999 Completed NIH AIDS Clinical Trials Information Service NA
NCT00001061 Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS https://ClinicalTrials.gov/show/NCT00001061 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00001034 The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV https://ClinicalTrials.gov/show/NCT00001034 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00000989 The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS https://ClinicalTrials.gov/show/NCT00000989 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00000894 Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis https://ClinicalTrials.gov/show/NCT00000894 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2000-06-30
NCT00000836 A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT) https://ClinicalTrials.gov/show/NCT00000836 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00000799 HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol https://ClinicalTrials.gov/show/NCT00000799 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00000766 CMV Retinitis Retreatment Trial https://ClinicalTrials.gov/show/NCT00000766 Completed National Institute of Allergy and Infectious Diseases (NIAID) 1995-09-30
NCT00000726 Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome https://ClinicalTrials.gov/show/NCT00000726 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00000698 A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV Retinitis https://ClinicalTrials.gov/show/NCT00000698 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00000693 Suppression of Cytomegalovirus Retinitis Utilizing High Dose Intravenous Acyclovir and Oral Zidovudine in Patients With AIDS https://ClinicalTrials.gov/show/NCT00000693 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00000691 A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure https://ClinicalTrials.gov/show/NCT00000691 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00000688 A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS https://ClinicalTrials.gov/show/NCT00000688 Completed National Institute of Allergy and Infectious Diseases (NIAID) 1995-02-28
NCT00000673 A Phase I/II Open-Labelled Trial of Intravitreal Ganciclovir Salvage Therapy for AIDS Patients With Active CMV Retinitis Who Are Intolerant of Systemic Therapy https://ClinicalTrials.gov/show/NCT00000673 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00000668 A Phase I Pharmacokinetic and Tolerance Study of 28-Day Regimens of Oral Ganciclovir https://ClinicalTrials.gov/show/NCT00000668 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00000665 Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component https://ClinicalTrials.gov/show/NCT00000665 Completed National Institute of Allergy and Infectious Diseases (NIAID) 1992-04-30
NCT00063765 Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye https://ClinicalTrials.gov/show/NCT00063765 Completed National Institutes of Health Clinical Center (CC) NA
NCT00002330 A Study of Two Forms of Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS https://ClinicalTrials.gov/show/NCT00002330 Completed NIH AIDS Clinical Trials Information Service NA
NCT00065455 Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT00065455 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001062 A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Eyes https://ClinicalTrials.gov/show/NCT00001062 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00004827 Study of Docosahexaenoic Acid (DHA) Supplementation in Patients With X-Linked Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT00004827 Completed FDA Office of Orphan Products Development NA
NCT00004794 Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis https://ClinicalTrials.gov/show/NCT00004794 Completed Office of Rare Diseases (ORD) NA
NCT00000143 Studies of Ocular Complications of AIDS (SOCA)–Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT) https://ClinicalTrials.gov/show/NCT00000143 Completed Johns Hopkins Bloomberg School of Public Health 2000-06-30
NCT00000142 Studies of the Ocular Complications of AIDS (SOCA)–HPMPC Peripheral CMV Retinitis Trial (HPCRT) https://ClinicalTrials.gov/show/NCT00000142 Completed Johns Hopkins Bloomberg School of Public Health 1996-02-29
NCT00000136 Studies of the Ocular Complications of AIDS (SOCA)–Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT) https://ClinicalTrials.gov/show/NCT00000136 Completed Johns Hopkins Bloomberg School of Public Health 1991-10-31
NCT00000135 Studies of the Ocular Complications of AIDS (SOCA)–Monoclonal Antibody CMV Retinitis Trial (MACRT) https://ClinicalTrials.gov/show/NCT00000135 Completed Johns Hopkins Bloomberg School of Public Health 1996-08-31
NCT00000134 Studies of the Ocular Complications of AIDS (SOCA)–Cytomegalovirus Retinitis Retreatment Trial (CRRT) https://ClinicalTrials.gov/show/NCT00000134 Completed Johns Hopkins Bloomberg School of Public Health 1995-03-31
NCT00000118 Ganciclovir Implant Study for Cytomegalovirus Retinitis https://ClinicalTrials.gov/show/NCT00000118 Completed National Eye Institute (NEI) NA
NCT00000116 Randomized Trial for Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT00000116 Completed National Eye Institute (NEI) NA
NCT00000114 Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT00000114 Completed National Eye Institute (NEI) NA

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03322930 Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP) https://ClinicalTrials.gov/show/NCT03322930 Completed Retina Foundation of the Southwest 2019-03-01
NCT03314207 Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP) https://ClinicalTrials.gov/show/NCT03314207 Recruiting Applied Genetic Technologies Corp 2021-12-31
NCT03281005 Development of Visual Function Evaluation Method https://ClinicalTrials.gov/show/NCT03281005 Completed Astellas Pharma Inc 2019-11-21
NCT03146078 Rate of Progression in USH2A-related Retinal Degeneration https://ClinicalTrials.gov/show/NCT03146078 Active, not recruiting Jaeb Center for Health Research 2023-01-31
NCT02759952 Clinical Characterization on PDE6A-related Retinitis Pigmentosa in Preparation to a Gene Therapy Trial https://ClinicalTrials.gov/show/NCT02759952 Enrolling by invitation STZ eyetrial 2025-12-31
NCT02575430 Natural History Study in Inherited Retinal Disease Subjects Caused by Mutations in RPE65 or LRAT https://ClinicalTrials.gov/show/NCT02575430 Completed QLT Inc. 2016-03-31
NCT02303288 Post-Market Study of the Argus® II Retinal Prosthesis System - France https://ClinicalTrials.gov/show/NCT02303288 Completed Second Sight Medical Products 2018-03-20
NCT01949623 Biomarkers In Retinitis Pigmentosa (BIRP) https://ClinicalTrials.gov/show/NCT01949623 Completed Johns Hopkins University 2017-06-30
NCT01876147 Visual and Functional Assessment in Low Vision Patients https://ClinicalTrials.gov/show/NCT01876147 Completed University of Oxford 2016-03-31
NCT01860092 New Enrollment Post-Approval Study of the Argus® II Retinal Prosthesis System https://ClinicalTrials.gov/show/NCT01860092 Active, not recruiting Second Sight Medical Products 2023-08-31
NCT01790958 Microcurrent Stimulation to Treat Macular Degeneration https://ClinicalTrials.gov/show/NCT01790958 Completed Retina Institute of Hawaii 2012-12-31
NCT03349242 Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR) https://ClinicalTrials.gov/show/NCT03349242 Recruiting MeiraGTx UK II Ltd 2022-12-30
NCT01431326 Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care https://ClinicalTrials.gov/show/NCT01431326 Completed Duke University 2019-11-30
NCT04312672 Long Term Follow-Up Gene Therapy Study for XLRP RPGR https://ClinicalTrials.gov/show/NCT04312672 Recruiting MeiraGTx UK II Ltd 2023-06-30
NCT04281732 Visual Performance Measures in a Virtual Reality Environment for Assessing Clinical Trial Outcomes in Those With Severely Reduced Vision https://ClinicalTrials.gov/show/NCT04281732 Recruiting Queen’s University, Belfast 2020-09-30
NCT03975543 Retrospective Natural History Study of Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT03975543 Active, not recruiting SparingVision 2019-07-31
NCT03901391 Prospective Open Clinical and Genetic Study of Patients With Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT03901391 Enrolling by invitation Sensor Technology for Deafblind 2020-10-01
NCT03753893 Ocular Manifestations in Rheumatic Diseases https://ClinicalTrials.gov/show/NCT03753893 Active, not recruiting Lawson Health Research Institute 2020-10-01
NCT03626207 Development of Visual Function Evaluation Method (2) https://ClinicalTrials.gov/show/NCT03626207 Completed Astellas Pharma Inc 2019-06-26
NCT01021982 Evaluation of Objective Perimetry Using Pupillometer https://ClinicalTrials.gov/show/NCT01021982 Completed Sheba Medical Center 2013-01-31
NCT02014389 Evaluation of Objective Perimetry Using Chromatic Multifocal Pupillometer https://ClinicalTrials.gov/show/NCT02014389 Recruiting Sheba Medical Center 2020-12-31
NCT04127006 Rate of Progression in EYS Related Retinal Degeneration https://ClinicalTrials.gov/show/NCT04127006 Recruiting Jaeb Center for Health Research 2024-01-31
NCT01432847 Cell Collection to Study Eye Diseases https://ClinicalTrials.gov/show/NCT01432847 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT00784901 Study of the Correlation Between Macular Thickness Analyzed by Optical Coherence Tomography and the Visual Functions in Retinitis Pigmemtosa https://ClinicalTrials.gov/show/NCT00784901 Completed National Taiwan University Hospital 2008-11-30
NCT00559234 Potential Research Participants for Future Studies of Inherited Eye Diseases https://ClinicalTrials.gov/show/NCT00559234 Completed National Institutes of Health Clinical Center (CC) NA
NCT00475254 Stress and Vision Fluctuations in Retinitis Pigmentosa https://ClinicalTrials.gov/show/NCT00475254 Completed Johns Hopkins University 2011-04-30
NCT00378742 Repository for Inherited Eye Diseases https://ClinicalTrials.gov/show/NCT00378742 Active, not recruiting National Institutes of Health Clinical Center (CC) NA
NCT00254605 Retinal Imaging in Patients With Inherited Retinal Degenerations https://ClinicalTrials.gov/show/NCT00254605 Recruiting University of California, San Francisco 2023-10-31
NCT00231010 Molecular Genetics of Retinal Degenerations https://ClinicalTrials.gov/show/NCT00231010 Completed National Institutes of Health Clinical Center (CC) NA
NCT00106743 Natural History and Genetic Studies of Usher Syndrome https://ClinicalTrials.gov/show/NCT00106743 Completed National Institutes of Health Clinical Center (CC) NA
NCT00091884 Efficacy of Elevated CD4 Counts on CMV Retinitis https://ClinicalTrials.gov/show/NCT00091884 Completed National Institutes of Health Clinical Center (CC) NA
NCT00341172 The Effects of Genetic Differences Among AIDS Patients on Cytomegalovirus Retinitis https://ClinicalTrials.gov/show/NCT00341172 Completed National Institutes of Health Clinical Center (CC) NA
NCT00005572 A Comparison of HIV-Infected Patients With and Without Opportunistic (AIDS-Related) Infection https://ClinicalTrials.gov/show/NCT00005572 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00000905 A Study to Evaluate the Effects of Stopping Maintenance Therapy for Cytomegalovirus (CMV) Retinitis After Effective Anti-HIV Therapy https://ClinicalTrials.gov/show/NCT00000905 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00016471 A Genetic Analysis of Usher Syndrome in Ashkenazi Jews https://ClinicalTrials.gov/show/NCT00016471 Completed National Center for Research Resources (NCRR) NA
NCT00001734 Screening for NEI Clinical Studies https://ClinicalTrials.gov/show/NCT00001734 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001611 Immune Activity Against CVM Retinitis https://ClinicalTrials.gov/show/NCT00001611 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001347 Study of Usher Syndromes, Type 1 and Type 2 https://ClinicalTrials.gov/show/NCT00001347 Completed National Institutes of Health Clinical Center (CC) NA
NCT00000168 Longitudinal Study of Ocular Complications of AIDS (LSOCA) https://ClinicalTrials.gov/show/NCT00000168 Completed Johns Hopkins Bloomberg School of Public Health 2013-08-31

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03319524 Clinical and Genetic Testing of Patients With Usher Syndrome https://ClinicalTrials.gov/show/NCT03319524 Completed Sensor Technology for Deafblind 2018-04-01
NCT02435940 Inherited Retinal Degenerative Disease Registry https://ClinicalTrials.gov/show/NCT02435940 Recruiting Foundation Fighting Blindness 2037-06-30
NCT01793168 Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford https://ClinicalTrials.gov/show/NCT01793168 Recruiting Sanford Health 2100-12-31
NCT04128150 High Resolution Retina Imaging https://ClinicalTrials.gov/show/NCT04128150 Recruiting Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts 2023-01-30
NCT03990727 Phenotype Correlates Genotype of Inherited Retina Dystrophies, Retinitis Pigmentosa, Con>Rod Dystrophies. https://ClinicalTrials.gov/show/NCT03990727 Recruiting MejoraVisionMD 2019-06-13